Assertio Holdings, Inc.
NASDAQ:ASRTDrug Manufacturers - Specialty & Generic
+$0.01 today
- Market cap
- $151.86M
- Beta
- 0.53
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$5.55
Volume 0.27M
Average 0.33M
ASRT Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Assertio Holdings, Inc.NASDAQ: ASRT
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $5.84M fell 37.0% year over year, behind the -9.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -3.5% a year.
Context
- Depreciation & amortization amounted to 25.3% of revenue in FY2025, up 4.6 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -37.0% toward the trailing-twelve-month pace of -9.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 30.01M USD
- Year-over-year change
- +16.2%
- 4-year CAGR
- +0.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.01M | +16.2% |
| FY2024 | 2024-12-31 | 25.83M | -8.5% |
| FY2023 | 2023-12-31 | 28.23M | -15.5% |
| FY2022 | 2022-12-31 | 33.4M | +14.9% |
| FY2021 | 2021-12-31 | 29.08M | — |
Depreciation & Amortization vs competitors
How ASRT compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -9.6% is the 4th highest of 10, against a peer median of -11.3%.
- Depreciation & amortization amounts to 26.0% of revenue for ASRT, versus a peer median of 5.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $26.58M USD | -9.6% | -3.5% | 26.0% | |
| LTM Jun 2025 | ₪8.45M ILS | +33.4% | +13.6% | 3.5% | |
| LTM Mar 2026 | $7.74M USD | -13.3% | +13.9% | 3.0% | |
| LTM Mar 2026 | $5.17M USD | +4.4% | -20.7% | 7.8% | |
| LTM Mar 2026 | $2.88M USD | -18.4% | -17.7% | 31.5% | |
| LTM Mar 2026 | $1.58M USD | -10.2% | -13.6% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1.21M USD | +8.3% | +36.2% | — |
| LTM Mar 2026 | $1.2M USD | -11.3% | -33.9% | 1.4% | |
| LTM Apr 2026 | $170.49K USD | -37.6% | -19.3% | 9.5% | |
| LTM Mar 2026 | $131K USD | -84.0% | -41.1% | — | |
| Peer median (excluding ASRT) | — | -11.3% | -17.7% | 5.6% | |
Competitors are the stored peer set for ASRT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (1.28M) | 109.63M | (331.94M) | (21.58M) | (30.38M) |
| Depreciation & Amortization | 29.08M | 33.4M | 28.23M | 25.83M | 30.01M |
| Deferred Income Tax | 0 | (80.38M) | 76.2M | 0 | 0 |
| Stock-Based Compensation | 3.55M | 7.5M | 9.16M | 5.01M | 3.45M |
| Change in Working Capital | (31.29M) | (13.01M) | 140K | 5.2M | (45.33M) |
| Accounts Receivables | (11K) | (996K) | 48.67M | (6.46M) | (65.99M) |
| Inventory | 4.27M | (6.59M) | (4.97M) | (9.58M) | 9.68M |
| Accounts Payables | (28.7M) | (10.11M) | (29.35M) | (1.26M) | (13.29M) |
| Other Working Capital | (6.85M) | 4.69M | (14.21M) | 22.5M | 24.27M |
| Other Non-Cash Items | 5.48M | 21.46M | 267.82M | 11.95M | 14.07M |
| Operating Cash Flow | 5.52M | 78.6M | 49.6M | 26.41M | (28.18M) |
| Capital Expenditures | (53K) | (274K) | (628K) | 0 | 0 |
| Acquisitions (Net) | (18.47M) | (42.4M) | 1.53M | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (98.61M) | (119.2M) |
| Sales of Investments | 0 | 0 | 2.19M | 49.69M | 115.38M |
| Other Investing Activities | 0 | 0 | 0 | 0 | (8.17M) |
| Investing Cash Flow | (18.53M) | (42.67M) | 3.1M | (48.91M) | (11.99M) |
| Debt Repayment | (9.84M) | (750K) | (10.5M) | 0 | 0 |
| Common Stock Issued | 44.86M | 7.02M | 0 | 0 | 0 |
| Common Stock Repurchased | (418K) | (838K) | (7.9M) | (350K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (5.58M) | (13.23M) | (25.8M) | 0 | (189K) |
| Financing Cash Flow | 29.03M | (7.79M) | (44.2M) | (350K) | (189K) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 16.02M | 28.13M | 8.5M | (22.85M) | (40.36M) |
| Free Cash Flow | 5.47M | 78.32M | 48.98M | 26.41M | (28.18M) |
Assertio Holdings, Inc.
NASDAQ:ASRT
Intrinsic Alpha fair value
Locked
Current Price
$23.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.